Cryptosporidiosis after treatment with fingolimod: a case report and pharmacovigilance review
Open Access
- 30 March 2020
- journal article
- review article
- Published by Springer Science and Business Media LLC in BMC Infectious Diseases
- Vol. 20 (1), 1-4
- https://doi.org/10.1186/s12879-020-04988-7
Abstract
Background: Cryptosporidium sp. are common intracellular parasites responsible of severe diarrhea in T-cell-immunocompromised patients. We report the first case of a woman who contracted cryptosporidiosis after treatment with fingolimod, a drug labeled for multiple sclerosis and responsible for marked lymphopenia. Case presentation: A 60-year-old woman was admitted for abdominal pain diarrhea and fever. The patient suffered from multiple sclerosis and had been treated with fingolimod from august 2017 to september 2018 time of occurrence of the first digestive symptoms. Stool culture was negative but parasitological examination was positive for Cryptosporidium sp. Blood biological examination profound lymphopenia of 240/mm3 [17 CD4/mm3 (7%) and 32 CD8/mm3 (14%)]. Fingolimod was stopped, and the patient was put on nitazoxanide 500 mg bid for 7 days. The diarrhea resolved and no relapse was observed. Six other cases were found in the Pharmacovigilance database. Conclusion: Physicians should be aware of this association and screen for Cryptosporidium in cases of diarrhea in patients treated with fingolimod. Patients should be aware of this risk and advise to take appropriate measures to avoid such contamination.This publication has 18 references indexed in Scilit:
- Human cryptosporidiosis in immunodeficient patients in France (2015–2017)Experimental Parasitology, 2018
- Infectious Complications of Multiple Sclerosis Therapies: Implications for Screening, Prophylaxis, and ManagementOpen Forum Infectious Diseases, 2018
- Efficacy and Safety of the Newer Multiple Sclerosis Drugs Approved Since 2010CNS Drugs, 2018
- Fingolimod hydrochloride for the treatment of relapsing remitting multiple sclerosisExpert Opinion on Pharmacotherapy, 2017
- Sphingosine 1-Phosphate Receptor Modulators for the Treatment of Multiple SclerosisNeurotherapeutics, 2017
- Estimates of global, regional, and national morbidity, mortality, and aetiologies of diarrhoeal diseases: a systematic analysis for the Global Burden of Disease Study 2015The Lancet Infectious Diseases, 2017
- Human cryptosporidiosis in EuropeClinical Microbiology & Infection, 2016
- A review of the global burden, novel diagnostics, therapeutics, and vaccine targets for cryptosporidiumThe Lancet Infectious Diseases, 2014
- Human immune responses in cryptosporidiosisFuture Microbiology, 2010
- Treatment of cryptosporidiosisExpert Review of Anti-infective Therapy, 2009